Clearmind Medicine posts update on CMND-100 first-in-human trial webinar insights
CMND•Early Phase I/IIa trial update
Clearmind Medicine published an update on early real-world insights from its ongoing first-in-human Phase I/IIa CMND-100 trial in alcohol use disorder.
Investigators cited a generally positive early impression, citing recruitment progress and no meaningful adverse events or cardiac safety concerns to date.
MEAI profile and treatment model
The update highlighted MEAI’s non-hallucinogenic profile as a potential enabler of a simpler outpatient treatment model.
